(IN BRIEF) Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in moderate or severe exacerbations at 52 weeks. However, the AERIFY-2 study did not achieve the … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged adverse events, AERIFY-1, AERIFY-2, Chronic obstructive pulmonary disease, clinical trials, COPD, COVID-19, drug efficacy, Exacerbations, IL33, Itepekimab, moderate exacerbations, monoclonal antibody, partnership, phase 3 study, Regeneron, regulatory authorities, research and development, Sanofi, severe exacerbations, therapeutic development
(IN BRIEF) Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly improves lung function in patients with uncontrolled asthma, compared to dual-combination ICS/LABA therapy. The trials demonstrate the potential of Breztri … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alberto Papi, asthma, AstraZeneca, BioPharmaceuticals R&D, Breztri Aerosphere, budesonide/glycopyrronium/formoterol, chronic respiratory disease, clinical trials, COPD, global asthma statistics, ICS/LABA, KALOS, LOGOS, lung function, Phase III, regulatory authorities, Sharon Barr, triple-combination therapy
(IN BRIEF) AstraZeneca has completed clinical studies to transition Breztri, its inhaled treatment for COPD, to a next-generation propellant with 99.9% lower Global Warming Potential. This change aligns with AstraZeneca’s commitment to reducing its environmental impact through its Ambition Zero … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Breztri, COPD, eco-friendly, Honeywell, Low-Impact Inhalers, partnership, Professor Omar Usmani, sustainability
(IN BRIEF) GSK has submitted a regulatory application to the European Medicines Agency (EMA) to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. The … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adults Aged 50-59, COPD, GSK, NCT05590403, RSV Vaccination, vaccine
(IN BRIEF) In a significant development, the second investigational Phase 3 trial of Dupixent® (dupilumab) for chronic obstructive pulmonary disease (COPD), known as NOTUS, has demonstrated promising results. The trial found that Dupixent reduced COPD exacerbations by 34% compared to … Read the full press release
Posted in Business, Education, France, Healthcare, Management, News, Pharma & Biotech, Science, Technology
Tagged COPD, Dupixent, Exacerbations, George D. Yancopoulos, Naimish Patel, NOTUS, Regeneron, Sanofi
(IN BRIEF) New research from the University of East Anglia has found that being vaccinated against Covid-19 can halve the risk of developing long Covid. The study, which is the largest of its kind and includes more than 860,000 patients, … Read the full press release
Posted in Education, Healthcare, Management, Media, News, Science, United Kingdom
Tagged anxiety, asthma, comorbidities, COPD, coronary heart disease, depression, Dr Eleana Ntatsaki, hospitalisation, immunosuppression, long Covid, overweight, Prof Vassilios Vassiliou, risk factors, smokers, study, type 2 diabetes, University of East Anglia, vaccinated, WOMEN
(PRESSEMITTEILUNG) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert , hat angekündigt, dass das Unternehmen auf seinem Immunology Investor Event, das am Dienstag, den 29. März ab 14:00 Uhr … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronisch entzündliche Erkrankungen, chronisch obstruktive Lungenerkrankung, COPD, dupilumab, Dupixent®, Immunologie, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetische Zytokine, TAILORED COVALENCY™, Typ-2-Entzündung
(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that the company will provide an update on its Immunology strategy at its Immunology Investor Event, which is taking place … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronic inflammatory diseases, Chronic obstructive pulmonary disease, COPD, dupilumab, Dupixent, immunology, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetic cytokines, Tailored Covalency®, type 2 inflammation
Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced it sold the global rights of its chronic obstructive … Read the full press release
Posted in Business, Healthcare, Management, News, Pharma & Biotech
Tagged Aclidinium bromide, Almirall S.A., Alvesco, AstraZeneca, biopharmaceutical, Bretaris, Chronic obstructive pulmonary disease, COPD, Covis Pharma, Covis Pharma Group, Duaklir, Eklira, formoterol, Genuair, Genuair device, global rights, inhaler, LABA, LAMA, long-acting beta2-agonist, long-acting muscarinic antagonist, medicines, Omnaris, Pressair, respiratory medicines, rights, Tudorza, Zetonna
A thousand people are needed for ground-breaking research being carried out by the University of Birmingham into an incurable lung condition. BIRMINGHAM, 12-Jun-2018 — /EuropaWire/ — Supported by the British Lung Foundation, Dr Elizabeth Sapey and Professor Robert Stockley, will be … Read the full press release
Brentford, United Kingdom, 17-May-2018 — /EuropaWire/ — GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018. Data presented … Read the full press release
LONDON, 20-Apr-2018 — /EuropaWire/ — Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life. GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the … Read the full press release
Philips joins COPD Foundation and family of late Leonard Nimoy in asking the world to #BreatheBoldly on social media to raise COPD awareness AMSTERDAM, 16-Nov-2016 — /EuropaWire/ — On World COPD Day, Royal Philips (NYSE: PHG, AEX: PHIA) is proud … Read the full press release
Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered patients’ need for rescue medication and had improved benefit-risk profile compared to Seretide, with … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged COPD, Novartis, Novartis' Ultibro® Breezhaler®, Seretide, Vasant Narasimhan
Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death worldwide by 2030 – exceeded only by heart disease and stroke1 By the time most people know they have COPD, … Read the full press release
Posted in Germany, Healthcare, Society
Tagged Boehringer Ingelheim, Chronic obstructive pulmonary disease, COPD, Dr. Richard Russell
OTEMTO® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto® Respimat® right from the initial stage when patients first need maintenance therapy* Head-to-head ENERGITO® study shows superior lung function improvements with Spiolto® Respimat® versus LABA/ICS FDC AMSTERDAM, 29-9-2015 … Read the full press release
Posted in Germany, Healthcare, Netherlands, Pharma & Biotech
Tagged Boehringer Ingelheim, COPD, Spiolto® Respimat®
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies showed NVA237 provided significant and clinically meaningful improvements in lung function in moderate-to-severe COPD patients[8],[9] In … Read the full press release
Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress LONDON, 8-9-2014 — /EuropaWire/ — AstraZeneca today announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa … Read the full press release
28-6-2013 — /europawire.eu/ — AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease. Upon completion of … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, COPD, Pearl Therapeutics
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?